Technophage , founding partner of Lxbio Pharmaceuticals, has attended to ECCMID 2023. Together with the clinical team from Israel, it was presented the results obtained in the Phase I/IIa, aimed to determine the safety and tolerability of multiple doses of TP-102 in subjects with uninfected and infected diabetic foot ulcers. It has been successfully concluded and the company is now preparing the next clinical phases.
– Case study 1 showed a methicillin-resistant Staphylococcus aureus infection persisting for 12 month that failed to respond to repeated debridement and antibiotic treatment.
– Case study 2 showed an acute osteomyelitis that was developed while on antibiotic treatment.
Local application of TP-102 together with standard of care lead to an improved outcome of these complicated diabetic foot infections and complete resolution after long-term follow-up.
TP-102 is being developed for the treatment of infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Phase I/IIa has been successfully concluded and the company is now preparing the next clinical phases.
LxBio will be responsible for the production and worldwide commercialization of TP102.
For access to the full presentation please follow the link: (https://www.linkedin.com/feed/update/urn:li:activity:7061388008482123776). The presentation contains clinical images that may be harmful or traumatizing to some sensitive people.